SCTX insider ownership: who sold, why, and what they still hold

What stands out

Three insiders bought shares: Behzad Aghazadeh (58K shares, $1.3M), Svetlana Lucas (3K shares, $45K) and David Parrot (2.7K shares, $40K). These are the first purchases by current officers or directors in the filings on record.Behzad Aghazadeh: purchase, Jul 24, 2026 · Svetlana Lucas: purchase, Jul 23, 2026 · David Parrot: purchase, Jul 23, 2026

No officer or director sold shares in this period. 7 are left out

Left out: Behzad Aghazadeh, Benjamin Oakes, Svetlana Lucas, David Parrot, Joshua Bleharski, James Watson and Carl Gordon (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Recent activity

Past 30 days, Sep 14, 2026 to Oct 13, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Jul 28, 2026Behzad Aghazadeh bought 7.9K shares ($144K).

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Behzad Aghazadeh Director	7,905	$18.25	n/a	n/a	Jul 28, 2026	Jul 28, 2026

Outside holders, reported separately

ELI LILLY & Co, Jennifer Doudna and Brett Staahl and 3 more reported no open-market sales in the past 12 months. Large shareholders and the funds or companies that board members represent are not part of management, so they are left out of the figures above.

Details

Common questions

Is the Scribe Therapeutics, Inc. CEO selling stock?

No. Benjamin Oakes reported no open-market sales in the past 12 months.

Are any Scribe Therapeutics, Inc. insiders buying?

Yes. 3 officers or directors reported 5 purchases in the past 12 months (Form 4 code P; rows the filings describe as reinvested dividends, plan purchases, private deals or moves into the person's own trust are not counted).

The evidence

Who sold0 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan

Board members representing outside shareholders, reported separately: Carl Gordon. Details

Outside holder, reported separately: ELI LILLY & Co (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Jennifer Doudna (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: Brett Staahl (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: AH Bio Fund II, L.P. (a 10% owner, not part of management). No open-market sales reported in the period. Latest filing

Outside holder, reported separately: ORBIMED ADVISORS LLC (an outside shareholder, not part of management). No open-market sales reported in the period. Latest filing

The full ownership picture0 of 7 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 13, 2025

Sold

Held Oct 13, 2026

Still held

Behzad Aghazadeh

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Behzad Aghazadeh are complete.

Director

n/a

Vesting, gifts, unvested awards and holding lines for Behzad Aghazadeh

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Behzad Aghazadeh are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,725	$15.00	Jul 22, 2036	$48K

Estimate: options held × ($18.25 − strike price), using the most recent insider trade price on Form 4 (Jul 28, 2026), not a market close.

Benjamin Oakes

President, CEO, Director

n/a

Vesting, gifts, unvested awards and holding lines for Benjamin Oakes

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Benjamin Oakes are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
12,969	$19.13	Mar 12, 2036	$0
25,330	$3.08	Jun 7, 2030	$384K
101,320	$6.40	Aug 5, 2031	$1.2M
35,462	$6.40	Mar 20, 2035	$420K
264,784	$15.00	Jul 22, 2036	$861K
429,599	$15.00	Jul 22, 2036	$1.4M

Estimate: options held × ($18.25 − strike price), using the most recent insider trade price on Form 4 (Jul 28, 2026), not a market close.

Svetlana Lucas

Chief Business Officer

n/a

Vesting, gifts, unvested awards and holding lines for Svetlana Lucas

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Svetlana Lucas are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
9,547	$19.13	Mar 12, 2036	$0
34,490	$2.85	Jun 16, 2029	$531K
13,016	$3.08	Jun 7, 2030	$197K
21,108	$6.40	Aug 5, 2031	$250K
13,171	$6.40	Mar 20, 2035	$156K
109,426	$15.00	Jul 22, 2036	$356K
109,426	$15.00	Jul 22, 2036	$356K

Estimate: options held × ($18.25 − strike price), using the most recent insider trade price on Form 4 (Jul 28, 2026), not a market close.

David Parrot

Chief Financial Officer

n/a

Vesting, gifts, unvested awards and holding lines for David Parrot

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for David Parrot are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
8,909	$19.13	Mar 12, 2036	$0
100,462	$6.40	Dec 15, 2031	$1.2M
13,171	$6.40	Mar 20, 2035	$156K
109,426	$15.00	Jul 22, 2036	$356K
109,426	$15.00	Jul 22, 2036	$356K

Estimate: options held × ($18.25 − strike price), using the most recent insider trade price on Form 4 (Jul 28, 2026), not a market close.

Joshua Bleharski

Director

n/a

Vesting, gifts, unvested awards and holding lines for Joshua Bleharski

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Joshua Bleharski are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,725	$15.00	Jul 22, 2036	$48K

Estimate: options held × ($18.25 − strike price), using the most recent insider trade price on Form 4 (Jul 28, 2026), not a market close.

James Watson

Director

n/a

Vesting, gifts, unvested awards and holding lines for James Watson

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for James Watson are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,725	$15.00	Jul 22, 2036	$48K

Estimate: options held × ($18.25 − strike price), using the most recent insider trade price on Form 4 (Jul 28, 2026), not a market close.

Carl Gordon

Director

n/a

Vesting, gifts, unvested awards and holding lines for Carl Gordon

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Carl Gordon are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
14,725	$15.00	Jul 22, 2036	$48K

Estimate: options held × ($18.25 − strike price), using the most recent insider trade price on Form 4 (Jul 28, 2026), not a market close.

Holdings and share of stake for Scribe Therapeutics, Inc. are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

Board members representing outside shareholders (1)Listed and sourced; not part of the management totals or the answer line

Directors whose reported holdings sit mostly in an investment fund or a corporate shareholder they represent, not in their own name, with beneficial ownership disclaimed except for their own financial interest. Listed and sourced here; not part of the management totals or the answer line. Shares a fund hands to its own investors are distributions, not sales.

Board member	Held Oct 13, 2025	Sold	Held Oct 13, 2026	Still held
Carl Gordon ! Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Carl Gordon are complete. Director	n/a	0	n/a	n/a
Vesting, gifts, unvested awards and holding lines for Carl Gordon Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Carl Gordon are complete; balances and unit counts will be added when the check is finished. 0gifted (net of own trusts)

Known gaps and uncertainty7 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Scribe Therapeutics, Inc. are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology25 filings on record, 25 filed in the 12-month period, and how we read them

All 25 Forms 3, 4 and 5 on record for Scribe Therapeutics, Inc. (SEC CIK 1853921), filed from Jul 23, 2026 to Jul 29, 2026; 25 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 13, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Scribe Therapeutics, Inc. insiders: what they own and what they did with it

What stands out

Recent activity

Outside holders, reported separately

Common questions

Is the Scribe Therapeutics, Inc. CEO selling stock?

Are any Scribe Therapeutics, Inc. insiders buying?

The evidence